Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Many unknowns, one thing we know for sure

<< Previous

Bullboard Posts

Next >>

Comment by fox7mfon Dec 20, 2023 8:45am

219 Views

Post# 35793412

RE:Many unknowns, one thing we know for sure

Hey Canadafan, I read your recent post on Yahoo suggesting investors watch for a big surprise concerning Oncy during the first week of Jan. I too believe something BD wise has to give soon, and as usual, your optimism is appreciated. Fingers crossed on that huge news, and merry merry to you, yours and all Oncy investors. We're due.

<< Previous

Bullboard Posts

Next >>

BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma-In-Situ: A Patient's Guide